Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sun Pharma gets US...

    Sun Pharma gets US subpoena over pricing of generic drugs

    Written by savita thakur thakur Published On 2016-05-31T12:37:57+05:30  |  Updated On 31 May 2016 12:37 PM IST
    Sun Pharma gets US subpoena over pricing of generic drugs
    The US Department of Justice (DoJ) has subpoenaed India's largest drug maker Sun Pharmaceutical Industries, seeking information about the pricing and marketing of the generic drugs it sells in the United States, the company said.

    The DoJ's antitrust division has also asked Sun Pharma's US unit for documents related to employee and corporate records and communications with competitors.


    The subpoena comes amid a wider probe by US regulators into steep increases in the prices of generic medicines in recent years.


    The US Department of Health and Human Services started an investigation last year into generic drug prices after prodding from US Senator Bernie Sanders and Democratic Representative Elijah Cummings.


    They specifically cited doxycycline hyclate 100 milligram, an antibiotic for which the price doubled in the year through June 2014.


    The DoJ's antitrust division sent subpoenas last year to two generic drugmakers — Endo International Plc and Mylan — seeking information on their doxycycline products.


    Sun Pharma, the world's fifth-largest maker of generic medicines, is one of several companies selling doxycycline products in the United States. In a statement issued late on Saturday, it did not disclose the products over which the DoJ had sought information.


    Other generic drug makers including India's Dr Reddy's Laboratories Ltd and US firm Allergan also received subpoenas from regulators seeking similar information last year, but they did not disclose the names of the products involved.

    doxycyclineDr Reddy's Laboratoriesgeneric drugsover pricingSun Pharma
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok